UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis

The Journal of neuroscience, 2011-06, Vol.31 (23), p.8329-8341

2011

Volltextzugriff (PDF)

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis

European journal of neurology, 2016-02, Vol.23 (2), p.412-415

2016

Volltextzugriff (PDF)

Validation of the functional assessment of multiple sclerosis quality of life instrument

Neurology, 1996-07, Vol.47 (1), p.129-139

1996

Volltextzugriff (PDF)

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

Journal of neuroimmunology, 2009-06, Vol.211 (1), p.124-130

2009

Volltextzugriff (PDF)

Novel Interventions with Favorable Resolution of Natalizumab-Induced Progressive Multifocal Leukoencephalopathy (PML) (P07.062)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P07-P07.062

2012

Volltextzugriff (PDF)

MRI and DTI Characteristics of Natalizumab Associated PML during a Novel Treatment Protocol (P07.061)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P07-P07.061

2012

Volltextzugriff (PDF)

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation–based conditioning regimen to prevent disease progression in patients with high disability scores

Blood, 2003-10, Vol.102 (7), p.2373-2378

2003

Volltextzugriff (PDF)

T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis : report on the first three patients

Bone marrow transplantation (Basingstoke), 1998-03, Vol.21 (6), p.537-541

1998

Volltextzugriff (PDF)

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2013-06, Vol.381 (9884), p.2167-2175

2013

Volltextzugriff (PDF)

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Lancet neurology, 2009-03, Vol.8 (3), p.254-260

2009

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.S01-S01.005

2012

Volltextzugriff (PDF)

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Blood, 1998-11, Vol.92 (10), p.3505-3514

1998

Volltextzugriff (PDF)

4-Aminopyridine in multiple sclerosis: prolonged administration

Neurology, 1991-09, Vol.41 (9), p.1344-1344

1991

Volltextzugriff (PDF)

Myogenic and central neurogenic factors in fatigue in multiple sclerosis

Multiple sclerosis, 1996-02, Vol.1 (4), p.236-241

1996

Volltextzugriff (PDF)

4-Aminopyridine improves clinical signs in multiple sclerosis

Annals of neurology, 1987-01, Vol.21 (1), p.71-77

1987

Volltextzugriff (PDF)

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

Lancet neurology, 2014-05, Vol.13 (5), p.472-481

2014

Volltextzugriff (PDF)

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Neurology, 2002-10, Vol.59 (7), p.998-1005

CHAMPS Study Group

2002

Volltextzugriff (PDF)

Composite methylation profiles of blood DNA as biomarkers for multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S284-S284

2008

Volltextzugriff (PDF)

Immunoablation with high-dose cyclophosphamide for refractory multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S181-S181

2008

Volltextzugriff (PDF)

Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S47-S47

2008

Volltextzugriff (PDF)

Autologous non-myeloablative hematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S34-S34

2008

Volltextzugriff (PDF)

Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis

American journal of ophthalmology, 2001-10, Vol.132 (4), p.463-471

CHAMPS Study Group

2001

Volltextzugriff (PDF)

PNL7 COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES: ASSESSING THE IMPACT OF NEUTRALIZING ANTIBODIES

Value in health, 2006-05, Vol.9 (3), p.A81-A81

2006

Volltextzugriff (PDF)

Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis

Annals of neurology, 1990-02, Vol.27 (2), p.186-192

1990

Volltextzugriff (PDF)

Treatment of RRMS patients with the PPARgamma agonist actos: results of a phase I trial

Aktuelle Neurologie, 2007, Vol.34 (S 2)

2007

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(53)
Tagungsberichte
(1)

Sprache

Englisch
(53)
Deutsch
(1)
Serbian
(1)

Erscheinungsjahr

n.n

Thema

Humans
(35)
Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Adult
(26)
Female
(24)
Middle Aged
(23)
Male
(21)
Neurosciences & Neurology
(20)
Biological And Medical Sciences
(19)
Clinical Neurology
(18)
Medical Sciences
(18)
Multiple Sclerosis
(10)
Neurology
(9)
Neurosciences
(9)
Multiple Sclerosis - Drug Therapy
(7)
Aged
(6)
Double-Blind Method
(6)
Magnetic Resonance Imaging
(6)
Multiple Sclerosis - Physiopathology
(6)
Multiple Sclerosis - Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(8)
Annals Of Neurology
(5)
Multiple Sclerosis
(5)
Blood
(4)
Lancet Neurology
(3)
Archives Of Neurology
(2)
British Journal Of Cancer
(2)
Experientia
(2)
Journal Of The Neurological Sciences
(2)
The Lancet Neurology
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis

Validation of the functional assessment of multiple sclerosis quality of life instrument

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

Novel Interventions with Favorable Resolution of Natalizumab-Induced Progressive Multifocal Leukoencephalopathy (PML) (P07.062)

MRI and DTI Characteristics of Natalizumab Associated PML during a Novel Treatment Protocol (P07.061)

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation–based conditioning regimen to prevent disease progression in patients with high disability scores

T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis : report on the first three patients

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

4-Aminopyridine in multiple sclerosis: prolonged administration

Myogenic and central neurogenic factors in fatigue in multiple sclerosis

4-Aminopyridine improves clinical signs in multiple sclerosis

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Composite methylation profiles of blood DNA as biomarkers for multiple sclerosis

Immunoablation with high-dose cyclophosphamide for refractory multiple sclerosis

Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis

Autologous non-myeloablative hematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis

Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis

PNL7 COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES: ASSESSING THE IMPACT OF NEUTRALIZING ANTIBODIES

Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis

Treatment of RRMS patients with the PPARgamma agonist actos: results of a phase I trial

Suchergebnisse filtern